Regional Cancer Care Associates | Strategic Alliance Partners

The US Oncology Network announced that Regional Cancer Care Associates entered into a strategic relationship with The Network effective April 1, 2023

Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.

Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.

Refaat Hegazi, MD, PhD, MPH, discusses nutrition-related toxicities in oncology.

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Jim M. Koeller, MS FHOPA, discusses the heterogeneity of biologics.

Regional Cancer Care Associates LLC, one of the nation’s largest networks of oncology specialists, has appointed Iuliana Shapira, MD, its chief medical officer.

Terrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.

Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.

Andrew Jennis, MD a hematologist/oncologist at Hackensack Meridian Health, who specializes in the diagnosis and treatment of digestive cancers, discusses the Centers for Medicare & Medicaid Services’ Oncology Care Model, a value model in which there is the opportunity for shared savings for both oncologists and CMS, so long as oncology care is administered in a cost-efficient manner.

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.

Kathleen Toomey, MD, who specializes in hematology and medical oncology and practices at the Steeplechase Cancer Center, discusses the results of the TAILORx trial, which reported that some patients with early-stage breast cancer can avoid chemotherapy.

Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.

Seth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor T-cell therapy.

The primary goal of a cancer diagnosis is to end up with the best possible outcome, and there are always several highways of care, or bundles, to choose from.

Regional Cancer Care Associates has continued its expansion along the East Coast by adding 2 Connecticut-based cancer centers with 6 cancer specialists to its network of independent practices.

As insurers and the federal government look for ways to reduce costs in oncology, the division of care between large, academic institutions and smaller providers is undergoing a process of change, says Seth Berk, MD, chair of the Financial Audit Committee for Regional Cancer Care Associates (RCCA) and a Mount Holly, New Jersey, specialist in internal medicine, hematology and oncology.

Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.

Demmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.

Consolidation in the insurance industry and the pace of the rise in cost of general and specialty pharmaceuticals are the 2 factors in the healthcare industry that will most affect access and affordability.

Regional Cancer Care Associates, LLC, will now provide cancer care to patients in Maryland through four divisions in the greater Washington, DC area.

As long as bundles are tied to a desired clinical outcome of relevance to the patients, we can truly move toward value-based medicine and enable the Goldilocks formula of delivery: just the right amount of care, not too much, and not too little-every time.

We have been asked on numerous occasions why would almost 100 oncologists "give up their independence and identity in their community" and become part of Regional Cancer Care Associates (RCCA), a new entity with a single tax identification number?

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

"Are you making progress?" is one of the questions you are most frequently being asked as an oncologist-even in social settings.

Regional Cancer Care Associates will collaborate with OncLive to develop informative resources for oncology professionals that advance patient care.

Like you, I get up every day and look at the stack of journals I know I need to read but cannot imagine when I will find the time.